Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3-enriched parenteral nutrition for parenteral nutrition-associated liver impairment in critically ill adults
2019-003276-39Phase 4Active
- Sponsor
- Vall d'Hebron University Hospital
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of omega-3 fatty acid in intestinal failure-associated liver disease (IFALD) (2 arms), sponsored by Vall d'Hebron University Hospital. Primary endpoint: Change in gamma-glutamyl transferase. Started Oct 2019; status: active.
02
Drugs
omega-3 fatty acid
03
Conditions
intestinal failure-associated liver disease (IFALD)
Beyond the preview
Go deeper on 2019-003276-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003276-39.